Suara.com – British drug manufacturer AstraZeneca may have provided an incomplete view of the efficacy data the COVID-19 vaccine made from clinical trials The United States is large-scale, according to the US National Institute of Allergy and Infectious Diseases (NIAID), Tuesday (22/3/2021).
AstraZeneca claimed the day before that its COVID-19 vaccine, developed in collaboration with the University of Oxford, is 79 percent effective in preventing it internal disease symptoms large-scale trials in Chile, Peru, and the US.
“The DSMB expressed concern that AstraZeneca could have included old information from the clinical trial, which may have included an incomplete view of efficacy data,” the US agency said, referring to the independent Data Security Monitoring Board.
“We urge the companies concerned to work with the DSMB to review the efficacy data while ensuring that the most accurate latest data on efficacy is published as soon as possible.”
Also Read:
100 East Java Kiai Injected With Astrazeneca Vaccine Today
Source: Reuters/Antara
– .
